Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of pi3k inhibitors in the preparation of medicines for treating diseases related to thrombocytopenia

A thrombocytopenia and inhibitor technology, applied in the field of platelet-related drugs, can solve problems such as shortened platelet lifespan

Active Publication Date: 2021-06-15
SUZHOU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Technical problem to be solved: The pathogenesis of thrombocytopenia caused by different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and is cleared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of pi3k inhibitors in the preparation of medicines for treating diseases related to thrombocytopenia
  • Use of pi3k inhibitors in the preparation of medicines for treating diseases related to thrombocytopenia
  • Use of pi3k inhibitors in the preparation of medicines for treating diseases related to thrombocytopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] 1. Experimental mice

[0034] All experimental animal-related welfare is strictly implemented in accordance with the "Regulations on the Administration of Experimental Animals" of the People's Republic of China. Animal experiments were approved by the Medical Ethics Committee of Soochow University.

[0035] 2. Wash platelets

[0036] Healthy adult volunteers collected blood from the median vein of the elbow. Blood donors have no bad living habits such as smoking and drinking, and have not taken any drugs that affect platelet function within 2 weeks before blood donation. Female blood donors are not menstruating. All blood donors gave informed consent and signed the agreement. The experimental protocol was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and complied with the Declaration of Helsinki.

[0037]A certain amount of venous blood was drawn from a healthy person and anticoagulated with 1 / 7 volume of Acid-citratedextro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of PI3K inhibitors in the preparation of medicines for treating diseases related to platelet quantity reduction. For the first time, the role of PI3K in regulating the process of platelet clearance was experimentally explored, and it was proved that platelets in patients with thrombocytopenia undergo activation and apoptosis. Anti-Ibα antibody induces PI3K activation, PI3K activation activates Akt, and Akt mediates platelet activation and apoptosis. Akt regulates platelet apoptosis through phosphodiesterase-mediated activation of protein kinase A. Apoptotic and activated platelets expose PS and are phagocytized by macrophages in the liver. Inhibit PI3K activation, inhibit platelet activation and apoptosis, and block platelet clearance, indicating that PI3K inhibitors can be used for the treatment of diseases related to platelet quantity changes and inhibit the decrease of platelet quantity in peripheral circulating blood. Therefore, the above inhibitors have the potential to be developed into new platelets The potential of protective drugs and drugs for treating thrombocytopenic diseases is of great scientific and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related drugs, and in particular relates to the use of PI3K inhibitors in the preparation of drugs for treating diseases related to platelet count reduction. Background technique [0002] Thrombocytopenia is a common clinical symptom, which can lead to serious consequences of hemorrhage and even fatal internal hemorrhage. Thrombocytopenia-related diseases include immune thrombocytopenia, infection-induced thrombocytopenia, secondary thrombocytopenia, drug-induced thrombocytopenia, thrombocytopenia deficiency, non-immune thrombocytopenia, and decreased platelet production diseases, diseases caused by increased platelet destruction, or thrombotic thrombocytopenic purpura, etc. The pathogenesis of thrombocytopenia caused by these different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and the platelets are eliminated. Immune Thrombocytopenia (ITP) is a common a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P7/04
CPCA61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com